NC Judge Awards $57 Million to Durham Drug Company, Serenex
9/5/2008 7:18:43 AM
More...
|
Coserics Announces Company Formation Including Spin-Out of Phase 2 Clinical Asset From Serenex
4/17/2008 11:02:19 AM
More...
|
Serenex Announces Collaboration With National Cancer Institute to Initiate Clinical Trial With Serenex's Proprietary Small Molecule HSP90 Inhibitor, SNX-5422
2/27/2008 10:11:05 AM
More...
|
Serenex Announces Collaboration With National Cancer Institute to Evaluate Proprietary Small Molecule Hsp90 Inhibitors as a Potential Treatment for Lung Cancer
1/24/2008 9:44:50 AM
More...
|
Multiple Myeloma Research Foundation (MMRF) Grants $3.5 Million in Biotech Investment Awards
1/23/2008 10:59:39 AM
More...
|
Serenex and CHDI, Inc. Form Agreement to Evaluate Proprietary Small Molecule Hsp90 Inhibitors as a Potential Treatment for Huntington's Disease
1/17/2008 9:24:08 AM
More...
|
Serenex Announces Initiation of Second Phase 1 Trial for Oral Hsp90 Inhibitor, SNX-5422
12/4/2007 12:42:06 PM
More...
|
Serenex to Present at Acumen Biofin Rodman & Renshaw 9th Annual Healthcare Conference
10/23/2007 8:22:00 AM
More...
|
Serenex to Present at Biotechnology Industry Organization (BIO) Investor Forum 2007
10/9/2007 8:38:46 AM
More...
|
Serenex Announces Initiation of Phase 1 Trial for Oral Hsp90 Inhibitor, SNX-5422
5/31/2007 10:02:48 AM
More...
|
|